ADVENTRX, Pierre sign manufacturing contract for ANX-188 active ingredient

Pierre Fabre, as contract manufacturer, will produce the active ingredient in ANX-188 for use in clinical trials, including the Phase 3 study of ANX-188 that ADVENTRX plans to initiate in 2012.

Pierre Fabre pharmaceuticals division president Frederic Duchesne said, "We are convinced of the high potential of ANX 188, and our dedicated Supercritical Fluids unit, chosen by ADVENTRX to manufacture the ANX-188 active ingredient, will have the opportunity to put its cutting-edge expertise at the service of a unique manufacturing process."

Pierre Fabre developed highly technical manufacturing processes at its FDA-inspected facilities in Pau and Gaillac as a contract manufacturer for international pharmaceutical companies.

ADVENTRX chief executive officer Brian Culley said Pierre Fabre is an experienced manufacturer with a good reputation for quality that manufactures a number of products for commercial sale.

"Working with Pierre Fabre will enhance our proprietary position in the unique manufacturing process we have developed for ANX-188 and the long-term commercial value of ANX-188," Culley added.